Drugs / TNFR:Fc
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00001893 | Aug 1999 → Dec 2002 | asthma | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00012506 | — | juvenile idiopathic arthritis, uveitis | National Eye Institute (NEI) | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00001116 | ? → Jun 2000 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TNFR:Fc | “The purpose of this study is to determine if TNFR:Fc (a molecule that attaches to TNF) can lower the amount of IL-6 in HIV-positive patients.” NCT00001116 ↗ |
| Known as | Enbrel | “This study will investigate the safety and effectiveness of the drug Enbrel (TNFR:Fc) to treat uveitis (eye inflammation) in patients with juvenile rheumatoid arthritis.” NCT00012506 ↗1“Study of TNFR:Fc (Enbrel) in the Treatment of Asthma” NCT00001893 ↗ |
| Action | Inhibit | “binds to TNF-alpha and neutralizes its activity.” NCT00001116 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Soluble Tumor Necrosis Factor Receptor (TNFR:Fc)” NCT00001116 ↗ |
| Route | Subcutaneous | “subcutaneous injection” NCT00001893 ↗ |
| Target | TNF | “TNFR:Fc is a modification of a natural substance that binds to TNF-alpha and neutralizes its activity.” NCT00001116 ↗ |